Lightning Round: Medline is 'unbelievable', it's a buy, says Jim Cramer

Lightning Round Analysis - CNBC’s Mad Money with Jim Cramer

Key Concepts:

• Lightning Round: A rapid-fire segment on CNBC’s Mad Money where Jim Cramer provides quick opinions on individual stocks called in by viewers.
• ACA Marketplace: The Affordable Care Act marketplace for health insurance.
• UIPATH: A robotic process automation (RPA) software company.
• S&P 1000: A stock market index representing 1000 US companies.
• Snips and Chips: A trading strategy advocated by Cramer involving taking profits and reducing risk.
• Commoditized: A situation where products or services are largely indistinguishable, leading to price competition.

I. Healthcare Sector & Oscar Health (ALC)

The segment began with Matthew from Georgia inquiring about Oscar Health (ALC), a tech-focused, individualized health insurance provider operating within the ACA Marketplace. Matthew highlighted the company’s near 30% year-over-year membership growth and over 20% revenue growth, coupled with CEO Mark Bertolini’s commitment and the likely extension of ACA subsidies. Cramer’s response was conditional: he stated that Oscar’s success is heavily reliant on Bertolini remaining CEO, expressing his personal liking for the CEO. He implied that without Bertolini’s leadership, the stock’s potential is diminished.

II. Semiconductor & NVIDIA (NVDA) vs. SMCI

Linda from California asked about Super Micro Computer, Inc. (SMCI). Cramer’s response was blunt: “You want to own that area? You own NVIDIA. Period. End of story.” This demonstrates a strong preference for NVIDIA (NVDA) as the dominant player in the semiconductor space, dismissing SMCI as an inferior investment. This highlights Cramer’s belief in focusing on established leaders within a sector rather than smaller, potentially riskier plays.

III. Pharmaceutical & Alkermes (ALKS)

Dante from Texas sought Cramer’s opinion on Alkermes Pharmaceutical. Cramer expressed disappointment, stating, “By this point, something should have happened much better there than it has.” He recommended a “hold,” characterizing it as a “weak one,” indicating a lack of confidence in the stock’s potential for significant growth.

IV. Banking Sector – Huntington National Bank (HBAN) & KeyCorp (KEY)

William from Ohio inquired about Huntington National Bank. Cramer offered a positive assessment, stating they “always come through” and are “terrific.” He also recommended KeyCorp, echoing the same positive sentiment. This suggests Cramer views both banks as reliable and well-managed institutions.

V. Personal Anecdote & Goldman Sachs

Mark from New York shared a personal story about finding inspiration in Cramer’s previous coverage of Goldman Sachs, emphasizing the importance of perseverance. Cramer reciprocated, recounting his own repeated rejections from Goldman Sachs and drawing a parallel to his challenging relationship with Mark Haines, a former CNBC anchor. He described a period of conflict with Haines, stemming from negative commentary, which eventually evolved into a strong friendship. He stated, “He didn’t appreciate me. He didn’t appreciate the negative stuff I was sending him. So he put me on and we became great friends.”

VI. Robotic Process Automation – UiPath (PATH)

Mark continued by mentioning his stock, UiPath (PATH), had been added to the S&P 1000 after positive earnings and a pullback. Cramer expressed optimism about UiPath, praising CEO Robin Dines and suggesting the stock has upside potential, though acknowledging a potential need for further patience.

VII. Medical Devices – Smith & Nephew (SNPW)

Gil from Texas asked about Smith & Nephew. Cramer delivered a strongly negative opinion, stating the company “has to be sold.” He characterized the medical device market as “commoditized,” citing a personal anecdote about his wife’s knee replacement surgery where brand preference was irrelevant. He stated, “I asked my wife what knee she got a new knee. I said what did you use? Which one? She goes, it doesn't matter.” This illustrates his view that differentiation is lacking in this sector, leading to price-driven competition.

VIII. Medical Supply – Medline (Private)

Jack from Delaware inquired about Medline, a privately held medical supply company. Cramer offered an exceptionally bullish assessment, stating it was “unbelievable” and a “nine buys.” This is a significant endorsement, despite Medline not being publicly traded.

IX. Semiconductor – STM (STMicroelectronics)

Johnny from Washington asked about STM (STMicroelectronics). Cramer recommended a “buy,” noting the stock was “cheap” relative to its peers, despite trading at 40 times earnings. He justified this valuation by highlighting the company’s growth potential.

X. Constellation Energy (CEG) & Political Influence

Mike from Illinois described a profitable trade in Constellation Energy (CEG) that was negatively impacted by comments from former President Trump. Cramer advised selling the stock, stating that presidential involvement introduces too much uncertainty, especially when a substantial profit has already been realized. He emphasized the importance of securing gains and seeking new opportunities. He stated, “You’ve got a really big gain in the stock. It is time to move on.”

XI. Closing Remarks & Sponsorship

The segment concluded with Cramer announcing the end of the Lightning Round, sponsored by Charles Schwab. He then previewed upcoming segments, including a focus on semiconductor production expansion in the US.

Data & Statistics Mentioned:

• Oscar Health: Near 30% year-over-year membership growth, over 20% revenue growth.
• UiPath: Added to the S&P 1000.
• STM: Trading at 40 times earnings.

Synthesis/Conclusion:

This Lightning Round showcased Cramer’s rapid-fire, opinionated approach to stock analysis. He demonstrated a clear preference for established leaders in key sectors (NVIDIA in semiconductors), a cautious stance towards companies with unproven track records (Alkermes), and a willingness to react swiftly to external factors like political commentary (Constellation Energy). The segment highlighted the importance of CEO leadership (Oscar Health), market dynamics (commoditization in medical devices), and the need for disciplined profit-taking. Cramer’s responses were often direct and anecdotal, reflecting his characteristic style and providing viewers with quick, actionable insights.